Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Phase 1 Study to Investigate FP008 in Subjects with Advanced Solid Tumors
Details : FP008 is a Protein drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 25, 2025
A Study to Investigate FP002 in Subjects With Advanced Malignancies
Details : FP002 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 08, 2023
Lead Product(s) : FP002
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA
Details : FP002 is a humanized anti-CD47 IgG4 monoclonal antibody which binds and inhibits CD47 protein on the surface of tumor cells, triggering the recognition and elimination of cancer cells by the innate immunity.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : FP002
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
